Six Years Since Selinexor Approval for Relapsed Multiple Myeloma: What Have We Learned?

Samer Al Hadidi1, Rajshekhar Chakraborty2, Ghulam Rehman Mohyuddin3

  • 1Department of Hematology and Oncology, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA.

Abstract

No abstract available in PubMed .